ArticleJournal of translational medicine2025

Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib.

Jonatan Dewulf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.